fashion -WSS

fashion

author：focus 2025-09-28 01:34:44 - browse：3

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Researchers tackle phage therapy hurdles for wider adoption

WSS

What to know about the judge who will handle the Trump case

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Opioid cravings were reduced by anti

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Senators push IRS to launch nonprofit hospital probe

Ukraine seeks to reclaim its role as a hub for clinical trials

explore

fashion

Sign up for Morning Rounds

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Medical records are filled with copy

Idaho college killings prosecutors challenge defense's grand jury claims

Novavax promises a turnaround & Lilly roils the obesity market

BMS, looking to build heart drug business, turns to AI for diagnosis

Trump demands the U.S. pay no more for drugs than other countries … again

New CMS data security rules will hurt Medicare, Medicaid research

Moonlake's readout produced a cash windfall. Risks remain

Hospitals are dialing back on venture capital investing

focus

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Flagship Pioneering startup Sonata Therapeutics lays off 21

Flagship Pioneering startup Sonata Therapeutics lays off 21

New CMS data security rules will hurt Medicare, Medicaid research

Dozens dead from Maui wildfires: What we know about the victims

BMS, looking to build heart drug business, turns to AI for diagnosis

hotspot

hotspot

knowledge

Wikipedia